Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200176638> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4200176638 endingPage "S769" @default.
- W4200176638 startingPage "S768" @default.
- W4200176638 abstract "Abstract Background Our institution admits 650 patients annually for acute bacterial skin and skin structure infection (ABSSSI). These patients may require intravenous antibiotics, potentially complicated by social factors and loss to follow up. Dalbavancin is a long-acting lipoglycopeptide given as a single dose regimen for ABSSSI. A previous review conducted at our institution identified 117 potential avoidable hospital days over 4 months with outpatient dalbavancin use. The objective of this prospective study was to evaluate the clinical and financial impact of avoided admissions with outpatient dalbavancin use. Methods The Institutional Review Board approved this single-site, prospective study. All patients who presented to the emergency department (ED) with ABSSSI from December 15, 2020 to April 15, 2021 were included in the study. Dalbavancin eligibility criteria were given to providers. Eligible patients were given a single dose of dalbavancin and then discharged. The primary outcome was the difference between percentage of avoidable admissions from the ED with dalbavancin use in the retrospective cohort and prospective cohort. The secondary outcomes were estimated length of stay avoidance, percentage of treatment success without ED re-visit within 30 days, estimated hospital cost avoidance and drug cost reimbursement. The primary outcome was assessed using the Chi-square test. Descriptive statistics were used for the secondary outcomes. Results Fourteen patients received dalbavancin and avoided hospital admissions. The percentages of admissions avoided in the retrospective and prospective cohorts were 16.02% and 6.67%, respectively (Figure 1). A difference of 9.35% was found to be statistically significant (p=0.01). The total estimated length of stay avoidance was 50 days. No patients re-visited the ED within 30 days with treatment failure. The total estimated hospital cost avoidance was &148,852 (Table 1). The net reimbursement for dalbavancin over drug cost was &5,100 (Table 2). Conclusion Dalbavancin use decreased avoidable admissions. At our institution, annual hospital cost savings can reach &1,015,794 if dalbavancin was utlilized to all eligible patients. Disclosures All Authors: No reported disclosures" @default.
- W4200176638 created "2021-12-31" @default.
- W4200176638 creator A5041670715 @default.
- W4200176638 creator A5080920855 @default.
- W4200176638 creator A5081223980 @default.
- W4200176638 creator A5086686333 @default.
- W4200176638 creator A5087265162 @default.
- W4200176638 date "2021-11-01" @default.
- W4200176638 modified "2023-09-25" @default.
- W4200176638 title "1365. Clinical and Financial Implication of Dalbavancin Utilization on Length of Stay Avoidance in Acute Bacterial Skin and Skin Structure Infection" @default.
- W4200176638 doi "https://doi.org/10.1093/ofid/ofab466.1557" @default.
- W4200176638 hasPublicationYear "2021" @default.
- W4200176638 type Work @default.
- W4200176638 citedByCount "0" @default.
- W4200176638 crossrefType "journal-article" @default.
- W4200176638 hasAuthorship W4200176638A5041670715 @default.
- W4200176638 hasAuthorship W4200176638A5080920855 @default.
- W4200176638 hasAuthorship W4200176638A5081223980 @default.
- W4200176638 hasAuthorship W4200176638A5086686333 @default.
- W4200176638 hasAuthorship W4200176638A5087265162 @default.
- W4200176638 hasBestOaLocation W42001766381 @default.
- W4200176638 hasConcept C118552586 @default.
- W4200176638 hasConcept C126322002 @default.
- W4200176638 hasConcept C160735492 @default.
- W4200176638 hasConcept C162324750 @default.
- W4200176638 hasConcept C167135981 @default.
- W4200176638 hasConcept C187212893 @default.
- W4200176638 hasConcept C188816634 @default.
- W4200176638 hasConcept C194828623 @default.
- W4200176638 hasConcept C2778980435 @default.
- W4200176638 hasConcept C2779489039 @default.
- W4200176638 hasConcept C2779703844 @default.
- W4200176638 hasConcept C2780724011 @default.
- W4200176638 hasConcept C2781336494 @default.
- W4200176638 hasConcept C50522688 @default.
- W4200176638 hasConcept C523546767 @default.
- W4200176638 hasConcept C54355233 @default.
- W4200176638 hasConcept C71924100 @default.
- W4200176638 hasConcept C86803240 @default.
- W4200176638 hasConceptScore W4200176638C118552586 @default.
- W4200176638 hasConceptScore W4200176638C126322002 @default.
- W4200176638 hasConceptScore W4200176638C160735492 @default.
- W4200176638 hasConceptScore W4200176638C162324750 @default.
- W4200176638 hasConceptScore W4200176638C167135981 @default.
- W4200176638 hasConceptScore W4200176638C187212893 @default.
- W4200176638 hasConceptScore W4200176638C188816634 @default.
- W4200176638 hasConceptScore W4200176638C194828623 @default.
- W4200176638 hasConceptScore W4200176638C2778980435 @default.
- W4200176638 hasConceptScore W4200176638C2779489039 @default.
- W4200176638 hasConceptScore W4200176638C2779703844 @default.
- W4200176638 hasConceptScore W4200176638C2780724011 @default.
- W4200176638 hasConceptScore W4200176638C2781336494 @default.
- W4200176638 hasConceptScore W4200176638C50522688 @default.
- W4200176638 hasConceptScore W4200176638C523546767 @default.
- W4200176638 hasConceptScore W4200176638C54355233 @default.
- W4200176638 hasConceptScore W4200176638C71924100 @default.
- W4200176638 hasConceptScore W4200176638C86803240 @default.
- W4200176638 hasIssue "Supplement_1" @default.
- W4200176638 hasLocation W42001766381 @default.
- W4200176638 hasLocation W42001766382 @default.
- W4200176638 hasOpenAccess W4200176638 @default.
- W4200176638 hasPrimaryLocation W42001766381 @default.
- W4200176638 hasRelatedWork W1533727747 @default.
- W4200176638 hasRelatedWork W2510700473 @default.
- W4200176638 hasRelatedWork W2787439413 @default.
- W4200176638 hasRelatedWork W2897986878 @default.
- W4200176638 hasRelatedWork W2901929736 @default.
- W4200176638 hasRelatedWork W2907970638 @default.
- W4200176638 hasRelatedWork W3092029925 @default.
- W4200176638 hasRelatedWork W3133536779 @default.
- W4200176638 hasRelatedWork W3154944956 @default.
- W4200176638 hasRelatedWork W4232888950 @default.
- W4200176638 hasVolume "8" @default.
- W4200176638 isParatext "false" @default.
- W4200176638 isRetracted "false" @default.
- W4200176638 workType "article" @default.